Cargando…
Ifosfamide nephrotoxicity in adult patients
BACKGROUND: Ifosfamide, a widely prescribed antineoplasic agent, is frequently associated with kidney dysfunction. Its nephrotoxicity is well documented in children, but data are lacking in adult patients. METHODS: The aim of this retrospective study was to describe the clinical, biological and hist...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467602/ https://www.ncbi.nlm.nih.gov/pubmed/32897279 http://dx.doi.org/10.1093/ckj/sfz183 |
_version_ | 1783578048522616832 |
---|---|
author | Ensergueix, Gaël Pallet, Nicolas Joly, Dominique Levi, Charlène Chauvet, Sophie Trivin, Claire Augusto, Jean-Francois Boudet, Rémi Aboudagga, Hail Touchard, Guy Nochy, Dominique Essig, Marie Thervet, Eric Lazareth, Hélène Karras, Alexandre |
author_facet | Ensergueix, Gaël Pallet, Nicolas Joly, Dominique Levi, Charlène Chauvet, Sophie Trivin, Claire Augusto, Jean-Francois Boudet, Rémi Aboudagga, Hail Touchard, Guy Nochy, Dominique Essig, Marie Thervet, Eric Lazareth, Hélène Karras, Alexandre |
author_sort | Ensergueix, Gaël |
collection | PubMed |
description | BACKGROUND: Ifosfamide, a widely prescribed antineoplasic agent, is frequently associated with kidney dysfunction. Its nephrotoxicity is well documented in children, but data are lacking in adult patients. METHODS: The aim of this retrospective study was to describe the clinical, biological and histological characteristics of ifosfamide nephrotoxicity. RESULTS: We report 34 patients (median age: 41 years) admitted in six French nephrology departments for kidney failure and/or tubular dysfunction. Fifteen patients (44.1%) received cisplatin as part of their chemotherapy. In 6 patients (17.7%), ifosfamide nephrotoxicity was revealed by a proximal tubular dysfunction (PTD), in 5 patients (14.4%) by an acute kidney injury (AKI), in 6 patients (17.7%) by a chronic kidney disease (CKD) and in 17 patients (49.7%) by an association of PTD and AKI. Fourteen renal biopsies (41.2%) were performed and revealed acute tubular necrosis (85.7%), vacuolation (78.6%) and nuclear atypias (71.4%) of renal epithelial cells, interstitial inflammation (71.4%) and fibrosis (57.1%). Electron microscopy showed mitochondrial enlargement and dysmorphic changes suggestive of mitochondrial toxicity. Ten patients (29.4%) progressed to Stage 5 CKD, six (17.6%) required haemodialysis and six patients died during a median follow-up period of 31 months. Risk factors for Stage 5 CKD were age and cisplatin co-administration. |
format | Online Article Text |
id | pubmed-7467602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-74676022020-09-03 Ifosfamide nephrotoxicity in adult patients Ensergueix, Gaël Pallet, Nicolas Joly, Dominique Levi, Charlène Chauvet, Sophie Trivin, Claire Augusto, Jean-Francois Boudet, Rémi Aboudagga, Hail Touchard, Guy Nochy, Dominique Essig, Marie Thervet, Eric Lazareth, Hélène Karras, Alexandre Clin Kidney J Original Articles BACKGROUND: Ifosfamide, a widely prescribed antineoplasic agent, is frequently associated with kidney dysfunction. Its nephrotoxicity is well documented in children, but data are lacking in adult patients. METHODS: The aim of this retrospective study was to describe the clinical, biological and histological characteristics of ifosfamide nephrotoxicity. RESULTS: We report 34 patients (median age: 41 years) admitted in six French nephrology departments for kidney failure and/or tubular dysfunction. Fifteen patients (44.1%) received cisplatin as part of their chemotherapy. In 6 patients (17.7%), ifosfamide nephrotoxicity was revealed by a proximal tubular dysfunction (PTD), in 5 patients (14.4%) by an acute kidney injury (AKI), in 6 patients (17.7%) by a chronic kidney disease (CKD) and in 17 patients (49.7%) by an association of PTD and AKI. Fourteen renal biopsies (41.2%) were performed and revealed acute tubular necrosis (85.7%), vacuolation (78.6%) and nuclear atypias (71.4%) of renal epithelial cells, interstitial inflammation (71.4%) and fibrosis (57.1%). Electron microscopy showed mitochondrial enlargement and dysmorphic changes suggestive of mitochondrial toxicity. Ten patients (29.4%) progressed to Stage 5 CKD, six (17.6%) required haemodialysis and six patients died during a median follow-up period of 31 months. Risk factors for Stage 5 CKD were age and cisplatin co-administration. Oxford University Press 2019-12-31 /pmc/articles/PMC7467602/ /pubmed/32897279 http://dx.doi.org/10.1093/ckj/sfz183 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Ensergueix, Gaël Pallet, Nicolas Joly, Dominique Levi, Charlène Chauvet, Sophie Trivin, Claire Augusto, Jean-Francois Boudet, Rémi Aboudagga, Hail Touchard, Guy Nochy, Dominique Essig, Marie Thervet, Eric Lazareth, Hélène Karras, Alexandre Ifosfamide nephrotoxicity in adult patients |
title | Ifosfamide nephrotoxicity in adult patients |
title_full | Ifosfamide nephrotoxicity in adult patients |
title_fullStr | Ifosfamide nephrotoxicity in adult patients |
title_full_unstemmed | Ifosfamide nephrotoxicity in adult patients |
title_short | Ifosfamide nephrotoxicity in adult patients |
title_sort | ifosfamide nephrotoxicity in adult patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467602/ https://www.ncbi.nlm.nih.gov/pubmed/32897279 http://dx.doi.org/10.1093/ckj/sfz183 |
work_keys_str_mv | AT ensergueixgael ifosfamidenephrotoxicityinadultpatients AT palletnicolas ifosfamidenephrotoxicityinadultpatients AT jolydominique ifosfamidenephrotoxicityinadultpatients AT levicharlene ifosfamidenephrotoxicityinadultpatients AT chauvetsophie ifosfamidenephrotoxicityinadultpatients AT trivinclaire ifosfamidenephrotoxicityinadultpatients AT augustojeanfrancois ifosfamidenephrotoxicityinadultpatients AT boudetremi ifosfamidenephrotoxicityinadultpatients AT aboudaggahail ifosfamidenephrotoxicityinadultpatients AT touchardguy ifosfamidenephrotoxicityinadultpatients AT nochydominique ifosfamidenephrotoxicityinadultpatients AT essigmarie ifosfamidenephrotoxicityinadultpatients AT therveteric ifosfamidenephrotoxicityinadultpatients AT lazarethhelene ifosfamidenephrotoxicityinadultpatients AT karrasalexandre ifosfamidenephrotoxicityinadultpatients |